Neuropathy News and Research

RSS

Resection arthroplasty more effective for patients with diabetic foot ulcers

A recent study published in the March issue of Foot & Ankle International, the official scientific journal of the American Orthopaedic Foot & Ankle Society describes a possible amputation alternative for patients with neuropathic ulceration of the first metatarsophalangeal or big toe joint.

28 Apr 2011

CESAR, Saladax begin patient enrollment in paclitaxel CEPAC-TDM trial for NSCLC

In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer.

27 Apr 2011

Millennium submits two VELCADE sNDAs to FDA

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that it has submitted two supplemental new drug applications (sNDAs) for VELCADE® (bortezomib) for Injection to the U.S. Food and Drug Administration. The first application seeks to add a subcutaneous route of administration for VELCADE. The second application is for the use of VELCADE in combination with rituximab in patients with relapsed follicular non-Hodgkin lymphoma (NHL).

26 Apr 2011

Investigational Alzheimer's compounds may treat neuropathies

Drugs already in development to treat Alzheimer's disease may eventually be tapped for a different purpose altogether: re-growing the ends of injured nerves to relieve pain and paralysis.

15 Apr 2011

New guideline on most effective treatments for diabetic nerve pain

The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology, and will be presented April 11, 2011, at the American Academy of Neurology's Annual Meeting in Honolulu.

12 Apr 2011

New experimental drug can help treat peripheral neuropathy in cancer patients

Although oncologists have made great strides in many aspects of cancer treatment, one area that has remained very difficult to treat is peripheral neuropathy, namely pain that can be caused by the cancer or by its treatment.

11 Apr 2011

Sangamo prices public offering of 6.7M shares of common stock

Sangamo BioSciences, Inc. today announced the pricing of its previously announced public offering of 6,700,000 shares of its common stock at a price to the public of $7.70 per share. The public offering is expected to close on or around Wednesday, April 13, 2011, subject to customary closing conditions.

8 Apr 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics, Inc. today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation Annual Meeting in Paris, France.

7 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

Regular CT scans can cause secondary malignancies in older men with testicular cancer

UC Davis cancer researchers have found that older men with early-stage testicular cancer who opt for surveillance with regular CT scans over lymph node removal are at greater risk for secondary cancers.

31 Mar 2011

Diopsys launches new Vision Testing System to detect optic nerve disease

Diopsys, Inc. has launched the new Diopsys NOVA-DN VEP Vision Testing System to help optometrists and ophthalmologists detect optic nerve disease, including glaucoma and other neuro-visual disorders.

29 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Early intervention and close follow-up can help prevent hearing loss in children

Early intervention and close follow-up are key to rehabilitating hearing loss in children, says Paul R. Kileny, Ph.D., director of the University of Michigan's Audiology and Electrophysiology program.

25 Mar 2011

Diabetes management accepted for coverage by Chemical Abstracts

Future Medicine Ltd announces today that its new journal Diabetes Management (ISSN 1758-1907) which launched in January 2011 has been selected for coverage by Chemical Abstracts.

24 Mar 2011

Sports medicine physician suggests cardiac screening for young athletes requires augmentation of existing diagnostics to achieve greater accuracy, become cost-effective

Sports medicine physician Steve Watts says cardiac screening for young athletes is useful in preventing sudden cardiac death and suggests new diagnostics have the potential to add value and change the debate about the viability of cardiac screening for young athletes in the United States.

17 Mar 2011

DJO Global signs definitive agreement to purchase Rikco for $254.6 million

DJO Global, Inc., a leading provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced that one of its indirect subsidiaries has signed a definitive agreement to purchase Rikco International, LLC, D/B/A Dr. Comfort, for approximately $254.6 million in cash.

15 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients.

11 Mar 2011